Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
Vericel Corporation (NASDAQ:VCEL), a specialized company in advanced therapies for sports medicine and severe burn care, has announced its participation in the upcoming Bank of America Securities 2025 Healthcare Conference. The presentation is scheduled for Wednesday, May 14, 2025, at 12:20 p.m. ET (9:20 a.m. PT). Investors and interested parties can access the presentation webcast through the company's investor relations website at http://investors.vcel.com.
Vericel Corporation (NASDAQ:VCEL), azienda specializzata in terapie avanzate per la medicina sportiva e la cura delle ustioni gravi, ha annunciato la sua partecipazione alla prossima Bank of America Securities 2025 Healthcare Conference. La presentazione è prevista per mercoledì 14 maggio 2025, alle 12:20 ET (9:20 PT). Investitori e interessati possono seguire la presentazione in webcast tramite il sito web delle relazioni con gli investitori della società all'indirizzo http://investors.vcel.com.
Vericel Corporation (NASDAQ:VCEL), una empresa especializada en terapias avanzadas para medicina deportiva y atención a quemaduras graves, ha anunciado su participación en la próxima Conferencia de Salud 2025 de Bank of America Securities. La presentación está programada para miércoles 14 de mayo de 2025, a las 12:20 p.m. ET (9:20 a.m. PT). Los inversores y las partes interesadas pueden acceder a la transmisión en vivo de la presentación a través del sitio web de relaciones con inversores de la compañía en http://investors.vcel.com.
Vericel Corporation (NASDAQ:VCEL)는 스포츠 의학 및 중증 화상 치료를 위한 첨단 치료 전문 회사로, 다가오는 Bank of America Securities 2025 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 발표는 2025년 5월 14일 수요일 오후 12시 20분 ET (오전 9시 20분 PT)에 예정되어 있습니다. 투자자 및 관심 있는 분들은 회사 투자자 관계 웹사이트(http://investors.vcel.com)를 통해 발표 웹캐스트에 접속할 수 있습니다.
Vericel Corporation (NASDAQ:VCEL), une entreprise spécialisée dans les thérapies avancées pour la médecine sportive et le traitement des brûlures graves, a annoncé sa participation à la prochaine conférence Bank of America Securities Healthcare 2025. La présentation est prévue pour le mercredi 14 mai 2025 à 12h20 ET (9h20 PT). Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct de la présentation via le site des relations investisseurs de la société à l'adresse http://investors.vcel.com.
Vericel Corporation (NASDAQ:VCEL), ein auf fortschrittliche Therapien für Sportmedizin und schwere Brandverletzungen spezialisiertes Unternehmen, hat seine Teilnahme an der bevorstehenden Bank of America Securities 2025 Healthcare Conference angekündigt. Die Präsentation ist für Mittwoch, den 14. Mai 2025, um 12:20 Uhr ET (9:20 Uhr PT) geplant. Investoren und Interessierte können die Präsentation über den Webcast auf der Investor-Relations-Website des Unternehmens unter http://investors.vcel.com verfolgen.
- None.
- None.
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 Healthcare Conference at 12:20 p.m. ET (9:20 a.m. PT) on Wednesday, May 14, 2025.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
When is Vericel (VCEL) presenting at the Bank of America Healthcare Conference 2025?
How can investors watch Vericel's (VCEL) presentation at the Bank of America Healthcare Conference?
What markets does Vericel Corporation (VCEL) specialize in?
